Testing LB-P8 for people with primary sclerosing cholangitis
Part of Digestive system, Skin clinical trials.
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have PSC diagnosed by imaging (like a special X-ray of bile ducts).
- Your ALP (a liver enzyme) must be more than 1.5 times the normal upper limit at screening.
- You may also have inflammatory bowel disease (like ulcerative colitis or Crohn's disease).
- If you take certain medications (like steroids, biologics, or UDCA), you must be on a stable dose for at least 3 months before starting the trial.
- You cannot have cirrhosis (scarring of the liver) that is causing complications or a MELD score above 12.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HK-660S, for people with primary sclerosing cholangitis (PSC), a liver disease that affects the bile ducts. It aims to see if the drug can improve liver health and slow the disease.
This trial tests if a fecal microbiota transplant (FMT) can help people with primary sclerosing cholangitis (PSC) and inactive inflammatory bowel disease (IBD). It compares FMT against a placebo to see if it improves liver health.
This study follows adults with primary sclerosing cholangitis (PSC) over time to learn more about the condition. It is observational, meaning no new treatments are tested—just regular checkups and data collection to better understand PSC.
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
Hear when a new Primary Sclerosing Cholangitis (PSC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.